Vivus earnings beat expectations

25 February 2014

USA-based Vivus (Nasdaq: VVUS) has reported fourth-quarter and full-year 2013 financial results that beat analysts’ earnings expectation. Immediately following the release late Monday, shares rose over 4%, but fell close to 13% in premarket trading this morning.

For the fourth quarter, total net product revenue was $9.2 million, of which $7.7 million was from sales of weight-loss drug Qsymia V and the remaining amount was from Stendra/Spedra (avanafil). In addition, Vivus recognized $34.8 million in license revenue under its commercialization agreements with Auxilium and Sanofi related to Stendra or Spedra.

Net loss for the quarter was $17.2 million, or $0.17 net loss per share, as compared to a net loss of $56.7 million, or $0.56 net loss per share, during the fourth quarter of 2012.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK